We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$139M
AUM Growth
-$16.2M
Cap. Flow
-$1.33M
Cap. Flow %
-0.96%
Top 10 Hldgs %
71.95%
Holding
68
New
1
Increased
14
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$967K
2
DCGO icon
DocGo
DCGO
+$753K
3
PHR icon
Phreesia
PHR
+$306K
4
GOSS icon
Gossamer Bio
GOSS
+$281K
5
NKTR icon
Nektar Therapeutics
NKTR
+$276K

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.04M
2
BMY icon
Bristol-Myers Squibb
BMY
+$806K
3
PGNY icon
Progyny
PGNY
+$755K
4
BIIB icon
Biogen
BIIB
+$544K
5
TGTX icon
TG Therapeutics
TGTX
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 94.92%
2 Energy 2.82%
3 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$55.1M 39.65%
754,106
-12,000
-2% -$806K
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$8.37M 6.02%
89,240
+40
+0% +$3.39K
ELUT icon
3
Elutia
ELUT
$42M
$8.28M 5.96%
1,417,923
– –
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$6.71M 4.83%
59,684
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.38B
$4.83M 3.48%
199,400
– –
FHTX icon
6
Foghorn Therapeutics
FHTX
$305M
$4.48M 3.23%
294,143
-20,000
-6% -$274K
ALBO
7
DELISTED
Albireo Pharma Inc
ALBO
$3.37M 2.43%
113,000
– –
AXDX
8
DELISTED
Accelerate Diagnostics
AXDX
$3.24M 2.33%
225,239
– –
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$3.23M 2.32%
18,000
– –
CLR
10
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$2.37M 1.7%
38,600
– –
BIIB icon
11
Biogen
BIIB
$30.4B
$2.13M 1.53%
10,100
-2,500
-20% -$544K
BDSX icon
12
Biodesix
BDSX
$209M
$2.12M 1.52%
62,638
– –
KPTI icon
13
Karyopharm Therapeutics
KPTI
$216M
$1.99M 1.43%
17,955
+1,555
+9% +$194K
OVV icon
14
Ovintiv
OVV
$16.2B
$1.85M 1.33%
34,200
– –
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.66M 1.2%
14,000
+2,000
+17% +$249K
PRTA icon
16
Prothena Corp
PRTA
$453M
$1.53M 1.11%
41,978
+1,731
+4% +$62.4K
MASI
17
DELISTED
Masimo
MASI
$1.35M 0.97%
9,280
+1,280
+16% +$246K
ALKS icon
18
Alkermes
ALKS
$8.79B
$1.32M 0.95%
50,000
– –
HROW icon
19
Harrow
HROW
$1.74B
$1.23M 0.88%
180,000
– –
CORT icon
20
Corcept Therapeutics
CORT
$9.72B
$1.13M 0.81%
50,000
– –
INBX
21
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.12M 0.81%
50,448
+10,448
+26% +$267K
ETRN
22
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.12M 0.81%
133,050
– –
GOSS icon
23
Gossamer Bio
GOSS
$83.2M
$1.12M 0.81%
129,088
+29,088
+29% +$281K
DCGO icon
24
DocGo
DCGO
$64.3M
$1.02M 0.73%
110,000
+100,000
+1,000% +$753K
ARVN icon
25
Arvinas
ARVN
$517M
$1.01M 0.73%
15,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Birchview Capital held 68 positions worth $139M, down 10% from $155M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Birchview Capital's Q1 2022 filing shows 1 new, 14 increased, 5 reduced and 5 closed positions. Its largest new stake was Phreesia: 10,000 shares worth $264K. The largest sale was Arena Pharmaceuticals Inc, an estimated $2.04M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2022 buy was Phreesia: 10,000 shares worth $264K.
  • Birchview Capital added most to Soleno Therapeutics in Q1 2022, an estimated $967K increase.
  • Birchview Capital's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $806K.
  • Birchview Capital fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $2.04M.
  • Birchview Capital's ten largest holdings make up 72% of its $139M portfolio in Q1 2022.
  • Birchview Capital opened 1 new position and closed 5 in Q1 2022.
  • Birchview Capital's portfolio value fell 10% quarter-over-quarter to $139M.

Based on Birchview Capital's 13F filing for Q1 2022, filed 13 May 2022.